20Jan 2017


  • Faculty of Medicine, IbnSina National College, Jeddah, Saudi Arabia. Resident , Department of Urology Surgery, King Abdulaziz Medical city.
Crossref Cited-by Linking logo
  • Abstract
  • References
  • Cite This Article as
  • Corresponding Author

Renal cell carcinoma (RCC) represent 90% to 95% of malignant neoplasms developing from the kidney. Current advances in surgical and systemic treatments have actually significantly altered the management of RCC. Therefore, This review aimed to discuss and evaluate the most common complications and outcomes Associated with Surgical Management of Renal Cell Carcinoma, through different trails from all around the world, which are based evidence ones. We performed a comprehensive review of the literature based on free-text search in the National Library of Medicine Database MEDLINE using the following keywords: partial-nephrectomy, nephron-sparing surgery, cytoreductive-nephrectomy and metastatic renal cell carcinoma. Filtered for human trails, articles published in English to November 2016 were included in this article.

  1. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J ClinOncol. 2009;27(22):3584-3590.
  2. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373(9669):1119-1132.
  3. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006;98(18):1331-1334.
  4. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010;7(5):277-285.
  5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5-29. 2.
  6. Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol. 2005;23:202-212. 3.
  7. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865-875.
  8. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J ClinOncol. 2005;23:7889- 7896.
  9. Mickisch GH. Multimodality treatment of metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2002;2:681-685.
  10. Staehler M, Rohrmann K, Haseke N, Stief CG, Siebels M. Targeted agents for the treatment of advanced renal cell carcinoma. Curr Drug Targets. 2005;6:835-846.
  11. Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic RenalCell Carcinoma Database Consortium prognostic model: a populationbased study. Lancet Oncol. 2013;14:141-148.
  12. Wahlgren T, Harmenberg U, Sandstrom P, et al. Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000-2008). Br J Cancer. 2013;108:1541-1549.
  13. Ko JJ, Xie W, Kroeger N, et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol. 2015;16:293-300.
  14. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000;163:408-417. 11.
  15. Eton DT, Cella D, Bacik J, Motzer RJ. A brief symptom index for advanced renal cell carcinoma. Health Qual Life Outcomes. 2006;4:68.
  16. Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer. 1997;80:1198-1220.
  17. Yang JC, Topalian SL, Parkinson D, et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J ClinOncol. 1994;12:1572-1576.
  18. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of highdose and low-dose interleukin-2 in patients with metastatic renal cancer. J ClinOncol. 2003;21:3127-3132. 15.
  19. Lombardi G, Zustovich F, Donach M, Dalla Palma M, Nicoletto O, Pastorelli D. An update on targeted therapy in metastatic renal cell carcinoma. UrolOncol. 2012;30:240-246.
  20. Yezhelyev M, Master V, Egnatashvili V, Kooby DA. Combined nephrectomy and major hepatectomy: indications, outcomes, and recommendations. J Am Coll Surg. 2009;208:410-418.
  21. Staehler MD, Kruse J, Haseke N, et al. Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. World J Urol. 2010;28:543- 547.
  22. Dabestani S, Marconi L, Hofmann F, et al. Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol. 2014;15:e549-e561
  23. Gupta K, Miller J D, Li J Z, Russell M W, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34(3):193?205.
  24. Lam J S, Shvarts O, Leppert J T, Figlin R A, Belldegrun A S. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol. 2005;173(6):1853?1862.
  25. Escudier B. Emerging immunotherapies for renal cell carcinoma. Ann Oncol. 2012;23 08:viii35-40.
  26. de Peralta-Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma: A study of 101 cases.Am J SurgPathol.?2001;25:275?284.
  27. Cheville JC, Lohse CM, Zincke H, et al. Sarcomatoid renal cell carcinoma: An examination of underlying histologic subtype and an analysis of associations with patient outcome.Am J Surg Pathol.2004;28:435?441.
  28. Shuch B, Said J, La Rochelle JC, et al. Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology?is up-front resection indicated and, if not, is it avoidable??J Urol.?2009;182:2164?2171.
  29. Mian BM, Bhadkamkar N, Slaton JW, et al. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma.?J Urol.?2002;167:65?70.
  30. Tomera KM, Farrow GM, Lieber MM. Sarcomatoid renal carcinoma.?J Urol.?1983;130:657?659.
  31. Sella A, Logothetis CJ, Ro JY, et al. Sarcomatoid renal cell carcinoma. A treatable entity.?Cancer.1987;60:1313?1318.
  32. Shuch B, La Rochelle JC, Wu J, et al. Performance status and cytoreductive nephrectomy: Redefining management in patients with poor performance.?2008;113:1324?1331.
  33. Moch H, Gasser T, Amin MB, et al. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: A Swiss experience with 588 tumors.?2000;89:604?614.
  34. Blom JH, van Poppel H, Marechal JM, et al. Radical nephrectomy with and without lymph node dissection: Preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group.Eur Urol.?1999;36:570?575.
  35. Blute ML, Leibovich BC, Cheville JC, et al. A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma.J Urol.?2004;172:465?469.
  36. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial.?2001;358:966?970.
  37. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.N Engl J Med.?2001;345:1655?1659.
  38. Pantuck AJ, Belldegrun AS, Figlin RA. Cytoreductive nephrectomy for metastatic renal cell carcinoma: Is it still imperative in the era of targeted therapy?Clin Cancer Res.?2007;13:693s?696s.
  39. Kutikov A, Uzzo RG, Caraway A, et al. Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy.BJU Int.?2010;106:218?223.
  40. Flanigan R C, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford E D. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171(3):1071?1076.
  41. Trinh Q D Bianchi M Hansen J et al. In-hospital mortality and failure to rescue after cytoreductive nephrectomy EurUrol 2012(Sep):7
  42. Robson C J, Churchill B M, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol. 1969;101(3):297?301.
  43. Kerbl K, Clayman R V, McDougall E M, Kavoussi L R. Laparoscopic nephrectomy. BMJ. 1993;307(6917):1488?1489.
  44. Gill I S, Meraney A M, Schweizer D K. et al. Laparoscopic radical nephrectomy in 100 patients: a single center experience from the United States. Cancer. 2001;92(7):1843?1855.
  45. Chan D Y Cadeddu J A Jarrett T W Marshall F FKavoussi L R Laparoscopic radical nephrectomy: cancer control for renal cell carcinoma J Urol 200116662095?2099.2099, discussion 2099?2100
  46. Wille A H Roigas J Deger S T?llmann M T?rk I Loening S A Laparoscopic radical nephrectomy: techniques, results and oncological outcome in 125 consecutive cases EurUrol 2004454483?488.488, discussion 488?489
  47. HemalA K, Kumar A, Gupta N P, Kumar R. Oncologic outcome of 132 cases of laparoscopic radical nephrectomy with intact specimen removal for T1-2N0M0 renal cell carcinoma. World J Urol. 2007;25(6):619?626.
  48. Dunn M D, Portis A J, Shalhav A L. et al. Laparoscopic versus open radical nephrectomy: a 9-year experience. J Urol. 2000;164(4):1153?1159.
  49. McDougall E, Clayman R V, Elashry O M. Laparoscopic radical nephrectomy for renal tumor: the Washington University experience. J Urol. 1996;155(4):1180?1185.
  50. Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A, et al. A Prospective randomized EORTC Intergroup Phase 3 study comparing the complications of elective nephron sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2007;51:1606?15.
  51. Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc. 2000;75:1236?42.
  52. McKiernan J, Simmons R, Katz J, Russo P. Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology. 2002;59:816?20.
  53. Huang WC, Elkin EB, Levey AS, Jang TL, Russo P. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors-is there a difference in mortality and cardiovascular outcomes? J Urol. 2009;181:55?61.
  54. Kates M, Badalato GM, Pitman M, McKiernan JM. Increased risk of overall and cardiovascular mortality after radical nephrectomy for renal cell carcinoma 2 cm or less. J Urol. 2011;186:1247?53.
  55. Patard JJ, Shvarts O, Lam JS, Pantuck AJ, Kim HL, Ficarra V, et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol. 2004;171:2181?5.
  56. Becker F, Siemer S, Hack M, Humke U, Ziegler M, Stockle M. Excellent longterm cancer control with elective nephron-sparing surgery for selected renal cell carcinomas measuring more than 4 cm. Eur Urol. 2006;49:1058?63.
  57. Margulis V, Tamboli P, Jacobsohn KM, Swanson DA, Wood CG. Oncological efficacy and safety of nephron-sparing surgery for selected patients with locally advanced renal cell carcinoma. BJU Int. 2007;100:1235?9.

[Faisal Mansour Alsenani, Alfafsalah Aljohani, Ahmed hammad Aljohani and MeshalSaleh Ali Alsadeq. (2017); COMPLICATION AND OUTCOMES ASSOCIATED WITH SURGICAL MANAGEMENT OF RENAL CELL CARCINOMA: LITERATURE REVIEW. Int. J. of Adv. Res. 5 (1). 255-260] (ISSN 2320-5407). www.journalijar.com

Faisal Mansour Alsenani
Faculty of Medicine, Ibn Sina National College, Jeddah, Saudi Arabia.


Article DOI: 10.21474/IJAR01/2746       DOI URL: http://dx.doi.org/10.21474/IJAR01/2746

Share this article